PGAM
CRBP icon

Princeton Global Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Princeton Global Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-22
Closed -$3.25K – 505
2019
Q3 		$4K Hold
22
– – ﹤0.01% 321
2019
Q2 		$5K Hold
22
– – ﹤0.01% 345
2019
Q1 		$4K Buy
+22
New +$4.85K ﹤0.01% 316

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Princeton Global Asset Management's CRBP Position: Q4 2019 in Review

Princeton Global Asset Management sold out of Corbus Pharmaceuticals (CRBP) in Q4 2019, closing a stake of 22 shares — an estimated $3.25K sold.

Princeton Global Asset Management first reported a position in CRBP in Q1 2019 and held it in 3 quarters. The position peaked at $5K in Q2 2019. 105 funds tracked by Wall St. Rank hold CRBP as of Q4 2019.

  • Princeton Global Asset Management reported no remaining Corbus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Princeton Global Asset Management sold 22 Corbus Pharmaceuticals shares in Q4 2019, an estimated $3.25K.
  • Princeton Global Asset Management first reported a position in Corbus Pharmaceuticals in Q1 2019 and held it in 3 quarters.
  • Princeton Global Asset Management's Corbus Pharmaceuticals position peaked at $5K in Q2 2019.
  • 105 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2019.

Based on Princeton Global Asset Management's 13F filing for Q4 2019, filed 10 Feb 2020.